Heart Failure Drug Shows Promise in Phase III Clinical Trial
News Nov 12, 2012
Hospitalized heart failure patients who received the drug, serelaxin, in a phase III clinical trial had fewer disease symptoms and as a group experienced 37 percent fewer deaths over six months.
The results were presented Tuesday at the American Heart Association’s Scientific Sessions 2012 in Los Angeles by John Teerlink, MD, co-principal investigator of the study.
“Current therapy for acute heart failure has remained unchanged for decades,” said Teerlink, a UCSF professor of medicine and director of the heart failure program at the San Francisco Veterans Affairs Medical Center.
Teerlink continued, “Our findings suggest serelaxin holds promise as the first evidence-based therapy for acute heart failure to substantially improve patients’ symptoms and clinical outcomes, including death.”
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Microbiotica Enters into Microbiome Collaboration with GenentechNews
Strategic collaboration for microbiome biomarker signatures and therapeutic discovery based on Genentech’s inflammatory bowel disease pipeline.READ MORE
Chemoradiotherapy Before Surgery Could Extend Lives of Pancreatic Cancer PatientsNews
Pancreatic cancer patients treated with chemotherapy and radiotherapy before surgery may live longer than those who have immediate surgery, according to unpublished clinical trial results.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018